glp-1 discontinuation rates and Reinitiation of Dual-Labeled Receptor Agonists Among US Adults With Overweight or Obesity A harsh GLP-1 market reality:

[DOI] [PubMed] [Google Scholar] 22.Winchester J.F., Charen E., Ornillo C., Sheth N., Harbord N.B

You may have a case worth reviewing if: You used Ozempic, Wegovy, Rybelsus, or another GLP-1 drug You later developed sudden vision loss, blind spots, blurred vision, or a serious optic nerve condition You were diagnosed with NAION or another serious vision-related injury Your vision problems required emergency care, specialist treatment, or ongoing follow-up You have medical records, prescription history, or ophthalmology findings linking the vision event to the period when you used the drug Your loved one suffered severe or permanent vision loss after taking one of these medications Not every eye complaint will support a lawsuit

Small additions compound over a full day

The key advantage is portability to appointments without device dependence